/ Not yet recruitingNot Applicable A Phase III Randomized, Multicenter, Multinational, Double-Masked,Placebo-Controlled Study of Photrex™ (Rostaporfin) PhotodynamicTherapy in the Treatment of Classic and Occult Subfoveal ChoroidalNeovascularization Associated with Age-Related Macular Degeneration
A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
100 Clinical Results associated with Miravant Medical Technologies
0 Patents (Medical) associated with Miravant Medical Technologies
100 Deals associated with Miravant Medical Technologies
100 Translational Medicine associated with Miravant Medical Technologies